Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This is a phase II randomised, double-blind, dose finding, repeat dose Phase II multicentre
study of ODX for the treatment of patients with castration resistant prostate cancer (CRPC)
and skeletal metastases.
The primary objective is to evaluate the relative change from baseline in response markers
related to bone metabolism (alkaline phosphatase (B-ALP) and S P1NP) at 12 weeks of three
different doses of ODX (3.0, 6.0 and 9.0 mg/kg ODX).